By Counterforce Health Team in Hemgenix (etranacogene dezaparvovec) —

How to Get Hemgenix (etranacogene dezaparvovec) Covered by Aetna (CVS Health) in New Jersey: Prior Authorization, Appeals, and State Protections

Answer Box: Getting Hemgenix Covered by Aetna (CVS Health) in New Jersey

Aetna (CVS Health) requires prior authorization for Hemgenix (etranacogene dezaparvovec) in New Jersey. Adults with severe/moderately severe hemophilia B (Factor IX ≤2%) need: no inhibitors, current/historical prophylaxis use, and serious bleeding history. Submit the Aetna Hemgenix precertification form with factor IX labs, bleeding records, and hematologist consultation. Standard review takes 7-14 days; expedited decisions within 72 hours. If denied, New Jersey's IHCAP external review program provides independent medical review through Maximus Federal Services.

First step today: Contact your hematologist to gather factor IX activity levels, inhibitor testing, and bleeding history documentation.

Table of Contents

  1. Why New Jersey State Rules Matter
  2. Aetna's Prior Authorization Requirements
  3. Step-by-Step: Fastest Path to Approval
  4. New Jersey Step Therapy Protections
  5. Appeals Process and Timelines
  6. External Review Through IHCAP
  7. Common Denial Reasons & Solutions
  8. Costs and Patient Support
  9. When to Contact State Regulators
  10. FAQ

Why New Jersey State Rules Matter

New Jersey's insurance regulations work alongside Aetna's national policies to protect patients seeking specialty treatments like Hemgenix. The state's step therapy reform law (A1825), effective January 2026, will strengthen override protections for patients who've failed prior therapies or have contraindications.

Currently, New Jersey requires insurers to provide clear appeal processes and external review options. For hemophilia patients, this means additional safeguards when Aetna initially denies coverage based on medical necessity or experimental/investigational determinations.

Key state protections include:

  • 180-day internal appeal deadlines (longer than federal minimums)
  • Independent external review through IHCAP
  • Continuity of care protections during provider transitions
  • Clear timelines for urgent and standard decisions

Aetna's Prior Authorization Requirements

Aetna requires prior authorization for Hemgenix under their Clinical Policy Bulletin 1023. The drug appears on Aetna's 2025 precertification list for all product lines.

Coverage Criteria

Patient must meet all of the following:

  • Age ≥18 years
  • Severe or moderately severe hemophilia B (Factor IX activity ≤2% of normal)
  • No Factor IX inhibitors (≥0.6 Bethesda Units)
  • Current or historical use of Factor IX prophylaxis
  • History of life-threatening hemorrhage OR repeated serious spontaneous bleeding episodes
  • Prescribed by or in consultation with a hematologist

Required Documentation

Submit via the official Aetna Hemgenix precertification form:

Document Type Specific Requirements Timeline
Factor IX Activity Recent lab showing ≤2% normal activity Within 30 days
Inhibitor Testing Negative result (<0.6 BU) Within 30 days
Prophylaxis History ≥150 exposure days documented Historical records
Bleeding History Detailed diary or hospital records Past 12 months
Liver Function Normal enzymes, bilirubin ≤2x ULN Within 30 days
Hepatic Imaging Ultrasound/elastography ruling out abnormalities Within 3 months
Hematologist Consultation Medical necessity letter addressing all criteria Current

Step-by-Step: Fastest Path to Approval

Step 1: Pre-Authorization Preparation (Patient + Clinic)

Contact your hemophilia treatment center to schedule comprehensive evaluation. Gather insurance information and verify Aetna coverage details through the member portal.

Step 2: Clinical Documentation (Hematologist)

Order required labs and imaging within specified timeframes. Document bleeding episodes, prophylaxis failures, and treatment history in detail.

Step 3: Complete Aetna Form (Clinic Staff)

Download and complete the Hemgenix precertification request form. Include medical necessity letter addressing each coverage criterion.

Step 4: Submit Request (Clinic)

Submission options:

  • Fax: 1-888-267-3277 (specialty prior authorization)
  • Phone: 1-855-240-0535 (M-F, 8am-6pm CT)
  • Online: Through Aetna provider portal

Step 5: Track Decision (Patient + Clinic)

Standard review: 7-14 business days. For urgent cases, request expedited review (72-hour decision).

Step 6: Follow Up (If Needed)

If no decision within expected timeframe, call Aetna provider services. Request peer-to-peer review if initial denial occurs.

Step 7: Appeal Process (If Denied)

File internal appeal within 180 days. If unsuccessful, proceed to New Jersey external review through IHCAP.

New Jersey Step Therapy Protections

Starting January 1, 2026, New Jersey's enhanced step therapy law will provide stronger override protections. Currently, patients can request exceptions through Aetna's medical exception process.

Override Criteria (Effective 2026)

Exception granted when:

  • Required drug is contraindicated or likely to cause harm
  • Expected to be ineffective based on patient characteristics
  • Previously tried and discontinued due to lack of efficacy or adverse events
  • Not in patient's best interest based on medical necessity
  • Patient is currently stable on prescribed medication

Response timelines: 72 hours for non-urgent cases, 24 hours for urgent circumstances. Automatic approval if no response within deadline.

From our advocates: We've seen hemophilia patients successfully obtain step therapy overrides by documenting specific contraindications to first-line prophylaxis options, such as allergic reactions or inadequate bleeding control despite optimal dosing. Clear documentation of prior failures with dates and clinical outcomes strengthens these requests significantly.

Appeals Process and Timelines

Internal Appeals with Aetna

Level 1 Appeal:

  • Deadline: 180 days from denial notice
  • Timeline: 30 days for standard review, 72 hours for expedited
  • Submit to: Aetna appeals department (address on denial letter)
  • Required: Completed appeal form, additional clinical evidence, prescriber letter

Level 2 Appeal (if applicable):

  • Deadline: 60 days from Level 1 denial
  • Timeline: 30 days for standard review
  • Include: New evidence, peer-reviewed studies supporting medical necessity

Expedited Appeals

Request expedited review when delay would:

  • Seriously jeopardize life or health
  • Jeopardize ability to regain maximum function
  • Subject patient to severe pain

Contact Aetna urgently: 1-855-240-0535 for expedited processing.

External Review Through IHCAP

New Jersey's Independent Health Care Appeals Program (IHCAP), administered by Maximus Federal Services, provides independent medical review after internal appeals are exhausted.

Eligibility Requirements

  • Completed Aetna's internal appeal process
  • Denial based on medical necessity or experimental/investigational determination
  • Treatment is a covered service under your plan
  • Filing within 4 months of final internal denial

Filing Process

Submit to Maximus Federal Services:

  • Online: njihcap.maximus.com
  • Required documents: External appeal application, internal appeal decisions, medical records authorization
  • Filing fee: $25 (waivable for financial hardship)

Review Timeline

  • Standard review: 45 calendar days
  • Expedited review: 48 hours (for urgent cases)
  • Preliminary review: 5 business days to confirm eligibility

Important: IHCAP decisions are binding on Aetna. If overturned, Aetna must provide coverage as directed.

Common Denial Reasons & Solutions

Denial Reason Solution Strategy Required Documentation
"Experimental/Investigational" Cite FDA approval and clinical guidelines FDA label, peer-reviewed efficacy studies
"Medical necessity not established" Strengthen clinical justification Detailed bleeding history, prophylaxis failure documentation
"Alternative therapies available" Document prior treatment failures Pharmacy records, infusion logs, adverse event reports
"Incorrect site of care" Verify approved administration settings Hemophilia treatment center credentials
"Insufficient baseline documentation" Complete all required testing Recent labs, imaging, specialist consultation

Sample Appeal Language

"The patient meets all FDA-approved criteria for Hemgenix as outlined in Aetna's Clinical Policy Bulletin 1023. Despite optimized Factor IX prophylaxis with [specific product] at [dose/frequency], the patient experienced [number] serious bleeding episodes requiring emergency intervention over the past 12 months, documented in attached medical records."

Costs and Patient Support

Hemgenix list price: Approximately $3.5 million per dose

Financial Assistance Options

CSL Behring Support Programs:

  • Patient assistance programs (verify eligibility at manufacturer website)
  • Copay assistance for commercially insured patients
  • Case management support for insurance navigation

Foundation Grants:

  • National Hemophilia Foundation financial assistance
  • Patient Advocate Foundation copay relief programs
  • State pharmaceutical assistance programs (verify New Jersey eligibility)
Tip: Contact CSL Behring's patient support team early in the process. They often provide insurance navigation assistance and can help coordinate with specialty pharmacies.

When to Contact State Regulators

Contact the New Jersey Department of Banking and Insurance (DOBI) if:

  • Aetna fails to meet response timelines
  • Appeal process seems unfair or incomplete
  • You need assistance understanding your rights

DOBI Consumer Hotline: 1-800-446-7467 IHCAP-specific questions: 1-888-393-1062

For Medicare Advantage plans, contact Medicare directly at 1-800-MEDICARE for additional appeal rights.

FAQ

How long does Aetna prior authorization take for Hemgenix in New Jersey? Standard review takes 7-14 business days. Expedited reviews for urgent medical needs are completed within 72 hours. Complex cases may take up to 30 days.

What if Hemgenix is non-formulary on my Aetna plan? Submit a formulary exception request using Aetna's medical exception form. Include documentation of medical necessity and why formulary alternatives are inappropriate.

Can I request an expedited appeal if Aetna denies Hemgenix? Yes, if delay would seriously jeopardize your health or subject you to severe pain. Mark your appeal as "expedited" and provide supporting clinical documentation.

Does step therapy apply to Hemgenix if I've already failed prophylaxis outside New Jersey? Document all prior therapy attempts regardless of where they occurred. Aetna's policy recognizes historical treatment failures when properly documented.

What happens if I move to New Jersey while on Hemgenix therapy? New Jersey's continuity of care laws require up to 4 months of continued coverage for ongoing medically necessary treatment during provider network transitions.

How much does the IHCAP external review cost? $25 filing fee, which can be waived for financial hardship. Aetna pays all other review costs.

Sources & Further Reading

About Counterforce Health

Counterforce Health helps patients, clinicians, and specialty pharmacies navigate complex insurance approval processes for prescription drugs. Our platform transforms insurance denials into targeted, evidence-backed appeals by analyzing denial letters, plan policies, and clinical notes to identify specific denial reasons and draft point-by-point rebuttals aligned with each payer's requirements.

Disclaimer: This guide provides educational information about insurance processes and should not be considered medical advice. Always consult with your healthcare provider about treatment decisions and work with your clinical team for insurance navigation. For official guidance on New Jersey insurance regulations, contact the Department of Banking and Insurance at 1-800-446-7467.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.